Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,684 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06636552RecruitingPhase 2
Alternating drug combo plus daratumumab for newly diagnosed plasma cell leukemia
This trial tests a new treatment plan for people newly diagnosed with primary plasma cell leukemia (pPCL). It uses two different drug combinations that include daratumumab, given one after the other, followed by maintenance daratumumab. The goal is to see if this approach is safe and works well.
Athens, AtticaAges 18–80 - NCT07425795RecruitingPhase 2
Tislelizumab with chemo and radiation for first-line extensive SCLC
This trial tests a combination of an immunotherapy drug (tislelizumab), chemotherapy, and then radiation to the chest for people with extensive-stage small cell lung cancer who haven't had prior treatment. The goal is to see if this approach helps control the cancer longer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06585345RecruitingPhase 1/Phase 2
CD7 CAR-T for relapsed or refractory acute leukemia
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
Chengdu, SichuanAges 14–65 - NCT07415005RecruitingPhase 2
Lorlatinib and local therapy for ALK-positive lung cancer
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Houston, TexasAges 18 years+ - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT07401316Recruiting
Tracking germ cell tumors with a blood test for cancer DNA
This trial looks for signs of cancer DNA in your blood (circulating tumor DNA) to see if it can help track germ cell tumors. It may help doctors find out if your cancer is coming back earlier.
Indianapolis, IndianaAges 18 years+ - NCT06427629Recruiting
Eye cell imaging trial with moxifloxacin drops
This study uses a special camera to look at cells on the surface of your eye. It tests people using moxifloxacin eye drops either before eye surgery or for conditions like dry eye or Sjogren's syndrome.
SeoulAges 19–85 - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT07381972RecruitingPhase 3
Light and sound therapy for nodular skin cancer
This trial tests a new treatment that combines light (photodynamic therapy) and sound (sonodynamic therapy) to treat a common type of skin cancer called nodular basal cell carcinoma. The goal is to see if this combination works better than light alone for small tumors.
Jaú, São PauloAges 18 years+ - NCT03891706RecruitingPhase 1
Personalized T-cell therapy for advanced solid tumors
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
Guangzhou, GaungdongAges 18–70 - NCT04018729RecruitingPhase 2/Phase 3
Cell treatment through a breathing tube for severe emphysema
This trial tests a cell-based treatment placed into the lung using an airway valve, to help people with severe emphysema breathe easier. You may be eligible if your emphysema is uneven in the lungs and testing suggests your “collateral ventilation” is low, meaning the treatment area may benefit more from blocking airflow.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT06609928RecruitingPhase 1
CAR T cell therapy for children with relapsed AML that has FOLR1
This trial tests a special immune cell treatment (CAR T cells) that target a protein called FOLR1 found on some AML cells. It is for children aged 6 or younger whose leukemia has come back or not responded to treatment.
Seattle, WashingtonAges Up to 6 years - NCT06461182RecruitingPhase 2
PET Scan Test for Slow-Growing Lymphoma
This trial uses a special PET scan to take detailed pictures of slow-growing lymphomas, likely before or after your regular treatment scan. It may help your doctor see exactly where the lymphoma is in your body.
Taipei, BeitouAges 20–100 - NCT06362252RecruitingPhase 1/Phase 2
I-DXd plus atezolizumab for first-line extensive SCLC
This trial tests a new combination of drugs (I-DXd and atezolizumab, with or without carboplatin) as your first treatment for extensive stage small cell lung cancer. It has two groups: one for people who haven't started treatment yet, and another for those who've already had 4 cycles of a standard chemo-immunotherapy combination and are stable or better.
Birmingham, AlabamaAges 18 years+ - NCT07349498Recruiting
Heart health after stem cell transplant
This study follows patients who have had a stem cell transplant to see how their heart and blood vessels are doing over time. It helps doctors learn about long-term heart risks after transplant.
Beijing, Beijing MunicipalityAges Any age - NCT06878612RecruitingPhase 1
Personalized tumor cell vaccine for advanced solid tumors
This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.
Chengdu, SichuanAges 18–65 - NCT07341698Recruiting
Prehabilitation before stem cell transplant for blood cancer
This trial tests a prehabilitation program for patients with blood cancer who are scheduled for an allogeneic stem cell transplant. The goal is to help improve your physical and emotional strength before the transplant.
Copenhagen, DenmarkAges 18 years+ - NCT05701176Recruiting
Imaging scan to see how anti–PD-1 changes lung cancer cells
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
AmsterdamAges 18 years+ - NCT06364384RecruitingPhase 2
Chemo, radiation, and immunotherapy for rectal squamous cell carcinoma
This trial tests a combination of chemotherapy (cisplatin and 5-FU), radiation, and an immunotherapy drug (PD-1 antibody) for people with a rare type of rectal cancer that hasn't spread. The goal is to see if this treatment can shrink or eliminate the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06904131Recruiting
CAR-T cell therapy for advanced gynecological cancers
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05705687Recruiting
Testing a treatment plan for higher-risk testicular cancer
This trial checks whether a specific treatment approach works better for men with higher-risk non-seminomatous germ-cell tumors that have spread. Doctors will use tumor marker changes and where the cancer started (often the chest area) to help guide treatment choices.
VillejuifAges 16 years+ - NCT06792682RecruitingPhase 1
Cord blood cells for poor graft function after transplant
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07337161Recruiting
Radiation for skin cancer that spread to neck lymph nodes
This trial tests a focused radiation treatment after surgery for people with a common skin cancer (squamous cell carcinoma) that has spread to the lymph nodes in the neck or near the ear. The goal is to see if this approach can prevent the cancer from coming back.
London, OntarioAges 18 years+ - NCT07313020Enrolling by invitationEarly Phase 1
Handheld imaging to track stem cells in knee osteoarthritis
This trial tests a new handheld imaging device (MPI) to track stem cells injected into the knee. It aims to see if the device can safely monitor how the stem cells move and work in people with knee osteoarthritis.
Haikou, HainanAges 18–75
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,684 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.